[{"id":"5949ed40-8066-4fa3-b731-56d11b1c4969","acronym":"","url":"https://clinicaltrials.gov/study/NCT05546268","created_at":"2022-09-19T13:55:51.266Z","updated_at":"2024-07-02T16:34:27.290Z","phase":"Phase 1/2","brief_title":"Study of Oral MRT-2359 in Selected Cancer Patients","source_id_and_acronym":"NCT05546268","lead_sponsor":"Monte Rosa Therapeutics, Inc","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification • MYC expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • MRT-2359"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-06-11"},{"id":"c2c40e25-bf03-4412-bf0e-9712fe410547","acronym":"","url":"https://clinicaltrials.gov/study/NCT04947501","created_at":"2021-07-01T14:54:45.053Z","updated_at":"2024-07-02T16:34:27.282Z","phase":"Phase 1","brief_title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","source_id_and_acronym":"NCT04947501","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-06-11"},{"id":"5aa1495f-1183-4095-b05a-503274e48528","acronym":"","url":"https://clinicaltrials.gov/study/NCT04936529","created_at":"2021-06-23T17:52:37.826Z","updated_at":"2024-07-02T16:34:37.450Z","phase":"Phase 2","brief_title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","source_id_and_acronym":"NCT04936529","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • MYCN • CSF2","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-06-07"},{"id":"0f837c74-6645-47f4-8ca8-de1cded5acdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00911560","created_at":"2021-01-18T03:31:25.248Z","updated_at":"2024-07-02T16:34:38.224Z","phase":"Phase 1/2","brief_title":"Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma","source_id_and_acronym":"NCT00911560","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GD2-GD3 Vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 05/27/2009","start_date":" 05/27/2009","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"b59b27f1-de71-4f26-8ce2-01742271e9ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161519","created_at":"2023-12-08T15:15:31.906Z","updated_at":"2024-07-02T16:34:38.055Z","phase":"Phase 1/2","brief_title":"PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications","source_id_and_acronym":"NCT06161519","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLX038"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 11/14/2028","primary_completion_date":" 11/14/2028","study_txt":" Completion: 11/14/2033","study_completion_date":" 11/14/2033","last_update_posted":"2024-06-05"},{"id":"b461f5df-b759-4665-ad37-636f99b8f0e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06057948","created_at":"2023-09-28T15:10:58.229Z","updated_at":"2024-07-02T16:35:01.220Z","phase":"Phase 2","brief_title":"A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma","source_id_and_acronym":"NCT06057948","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/21/2023","start_date":" 09/21/2023","primary_txt":" Primary completion: 03/21/2026","primary_completion_date":" 03/21/2026","study_txt":" Completion: 03/21/2026","study_completion_date":" 03/21/2026","last_update_posted":"2024-05-24"},{"id":"1d61c822-8b23-4a8f-b429-8c238d66ec51","acronym":"HR-NBL2","url":"https://clinicaltrials.gov/study/NCT04221035","created_at":"2021-01-18T20:32:43.345Z","updated_at":"2024-07-02T16:35:03.584Z","phase":"Phase 3","brief_title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","source_id_and_acronym":"NCT04221035 - HR-NBL2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" MYCN • MYCL","pipe":" | ","alterations":" MYCN amplification • MYCL amplification","tags":["MYCN • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2024-05-15"},{"id":"b430b86f-67ea-42c5-b0ee-8244d57b79df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02245997","created_at":"2021-01-18T10:32:26.623Z","updated_at":"2024-07-02T16:35:07.642Z","phase":"","brief_title":"Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma","source_id_and_acronym":"NCT02245997","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-25"},{"id":"1fd5f0e8-8e90-49e8-8707-ca043ad0939b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02169609","created_at":"2021-01-18T10:06:37.044Z","updated_at":"2024-07-02T16:35:08.309Z","phase":"Phase 2","brief_title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","source_id_and_acronym":"NCT02169609","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/26/2014","start_date":" 11/26/2014","primary_txt":" Primary completion: 12/26/2016","primary_completion_date":" 12/26/2016","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2024-04-22"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2024-07-02T16:35:08.297Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-22"},{"id":"0130cadc-804e-436f-a2b2-19a2f539a6a6","acronym":"NCI-2018-03732","url":"https://clinicaltrials.gov/study/NCT03786783","created_at":"2021-01-18T18:43:54.532Z","updated_at":"2024-07-02T16:35:09.101Z","phase":"Phase 2","brief_title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT03786783 - NCI-2018-03732","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • IL6 • CXCL9","pipe":" | ","alterations":" MYCN amplification • IL6 expression","tags":["MYCN • IL6 • CXCL9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-04-17"},{"id":"5fcb443c-2b36-408f-a834-5fc190466658","acronym":"","url":"https://clinicaltrials.gov/study/NCT00904241","created_at":"2021-01-18T03:29:25.634Z","updated_at":"2024-07-02T16:35:09.485Z","phase":"","brief_title":"Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma","source_id_and_acronym":"NCT00904241","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 11/06/2000","start_date":" 11/06/2000","primary_txt":" Primary completion: 01/01/2100","primary_completion_date":" 01/01/2100","study_txt":"","study_completion_date":"","last_update_posted":"2024-04-16"},{"id":"25179c5b-c443-4dc5-8695-a99257e723d2","acronym":"PEDS-PLAN","url":"https://clinicaltrials.gov/study/NCT02559778","created_at":"2021-01-18T12:23:35.740Z","updated_at":"2024-07-02T16:35:10.996Z","phase":"Phase 2","brief_title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","source_id_and_acronym":"NCT02559778 - PEDS-PLAN","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • sorafenib • Zykadia (ceritinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-04-08"},{"id":"40e5938b-ca20-48e3-a63c-9af4d6ee2171","acronym":"","url":"https://clinicaltrials.gov/study/NCT05489887","created_at":"2022-08-05T13:57:17.217Z","updated_at":"2024-07-02T16:35:11.027Z","phase":"Phase 2","brief_title":"Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT05489887","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib) • Danyelza (naxitamab-gqgk)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 09/14/2022","start_date":" 09/14/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2033","study_completion_date":" 09/01/2033","last_update_posted":"2024-04-08"},{"id":"945e49ad-157e-4566-89d3-6b4ba4498abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04696029","created_at":"2021-01-19T20:49:35.193Z","updated_at":"2024-07-02T16:35:10.980Z","phase":"Phase 2","brief_title":"DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma","source_id_and_acronym":"NCT04696029","lead_sponsor":"Giselle Sholler","biomarkers":" TP53 • MYC • MYCN","pipe":" | ","alterations":" TP53 mutation • MYCN amplification • TP53 amplification","tags":["TP53 • MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MYCN amplification • TP53 amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-04-08"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"},{"id":"938d3f31-19a2-4d93-b968-94fc075d0fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03936465","created_at":"2021-01-18T19:23:12.104Z","updated_at":"2024-07-02T16:35:13.440Z","phase":"Phase 1","brief_title":"Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer","source_id_and_acronym":"NCT03936465","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN • BRD4 • BRD3","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • BRD4 • BRD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezobresib (BMS-986158) • trotabresib (BMS-986378)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 07/16/2024","study_completion_date":" 07/16/2024","last_update_posted":"2024-03-21"},{"id":"db508520-4ea9-4c84-8d31-9c56429ac8f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01798004","created_at":"2021-01-18T07:57:29.532Z","updated_at":"2024-07-02T16:35:15.000Z","phase":"Phase 1","brief_title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT01798004","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification • MYCN expression","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/08/2013","start_date":" 04/08/2013","primary_txt":" Primary completion: 07/28/2015","primary_completion_date":" 07/28/2015","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-13"},{"id":"149819dc-f2ee-4b82-83e1-8c607402853f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909777","created_at":"2021-01-18T14:16:53.862Z","updated_at":"2024-07-02T16:35:15.410Z","phase":"Phase 1","brief_title":"Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma","source_id_and_acronym":"NCT02909777","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification • MYC expression • MYCN expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYC expression • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fimepinostat (CUDC-907)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-03-11"},{"id":"365bcd51-2ab8-4615-b16d-85cc815ed781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505569","created_at":"2021-01-18T06:19:27.289Z","updated_at":"2024-07-02T16:35:17.700Z","phase":"","brief_title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","source_id_and_acronym":"NCT01505569","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYCN • CD34","pipe":" | ","alterations":" LDH elevation • MYCN amplification • MYCN expression","tags":["MYCN • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • MYCN amplification • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/20/2011","start_date":" 10/20/2011","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-26"},{"id":"e39a9176-8f33-40c0-84e2-27f9e52753ae","acronym":"MICCHADO","url":"https://clinicaltrials.gov/study/NCT03496402","created_at":"2021-01-18T17:12:56.304Z","updated_at":"2024-07-02T16:35:20.964Z","phase":"","brief_title":"Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)","source_id_and_acronym":"NCT03496402 - MICCHADO","lead_sponsor":"Institut Curie","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/20/2018","start_date":" 04/20/2018","primary_txt":" Primary completion: 04/19/2027","primary_completion_date":" 04/19/2027","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2024-02-05"},{"id":"d62d79f2-de52-4433-b2e3-056a8d934f77","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650648","created_at":"2021-01-18T12:54:13.814Z","updated_at":"2024-07-02T16:35:20.992Z","phase":"Phase 1","brief_title":"Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","source_id_and_acronym":"NCT02650648","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Danyelza (naxitamab-gqgk) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-02"},{"id":"7442a163-6eec-47a9-bb41-9d083af1512d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01857934","created_at":"2021-01-18T08:18:15.837Z","updated_at":"2024-07-02T16:35:23.492Z","phase":"Phase 2","brief_title":"Therapy for Children With Advanced Stage Neuroblastoma","source_id_and_acronym":"NCT01857934","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 07/05/2013","start_date":" 07/05/2013","primary_txt":" Primary completion: 10/21/2021","primary_completion_date":" 10/21/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-15"},{"id":"1548a7fc-808b-4731-ad11-a152caa3d099","acronym":"","url":"https://clinicaltrials.gov/study/NCT01757626","created_at":"2021-01-18T07:43:18.642Z","updated_at":"2024-07-02T16:35:24.430Z","phase":"Phase 1/2","brief_title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","source_id_and_acronym":"NCT01757626","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • Danyelza (naxitamab-gqgk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-05"}]